Infographic | July 12, 2022

HPAPI Outsourcing Drivers

Source: ISR Reports

In Q12022, ISR surveyed 100 sponsors who outsource highly potent small molecule drug substance manufacturing and asked them why their companies use CDMOs for the work. The data show the bulk of respondents are augmenting the supply they make in-house (42%). Another 27 percent of respondents (27%) have small molecule manufacturing capabilities, but do not have segregated manufacturing capabilities and one-quarter have no manufacturing capacity / outsource 100% of manufacturing. To learn more, follow the link to ISR’s Highly Potent Manufacturing Market Outlook report preview.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online